Onco-Summaries: Daily Oncology Updates at a Glance
- Oncofocus Team
- 4 days ago
- 1 min read
19/08/2026
Phase 3 INTerpath-001 trial shows individualized mRNA therapy + KEYTRUDA improves survival in resected melanoma (Ref)
Merck and Moderna announced that the Phase 3 INTerpath-001 trial evaluating intismeran autogene (V940/mRNA-4157), an individualized mRNA-based neoantigen therapy, in combination with KEYTRUDA® (pembrolizumab. anti-PD-1), achieved its primary endpoint of recurrence-free survival (RFS) and a key secondary endpoint of distant metastasis-free survival (DMFS) in patients with completely resected stage IIB–IV melanoma
The combination demonstrated clinically meaningful improvement compared to KEYTRUDA alone in the adjuvant melanoma setting
Safety profile was consistent with prior studies, with no new safety signals observed
Merck and Moderna plan to present full data at an upcoming international medical meeting and will engage regulators for potential submissions
Comments